The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning

Psychopharmacology

Volumn 220, Issue 4, 2012, Pages 799-807

  Stough, Con ^a   King, Rebecca ^a   Papafotiou, Katherine ^a   Swann, Phillip ^a   Ogden, Edward ^c   Wesnes, Keith ^b   Downey, Luke A ^a  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b United Biosource   (United Kingdom)

^c Victoria Police   (Australia)

Author keywords

CDR; Cognition; Ecstasy; MDMA; Memory; Methamphetamine; Psychomotor

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; CANNABIS; COCAINE; DIAMORPHINE; METHAMPHETAMINE; PLACEBO;

ACCURACY; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD LEVEL; CANNABIS SMOKING; COCAINE DEPENDENCE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ABUSE; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RESPONSE TIME; WORKING MEMORY; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; METHODOLOGY; PHOTOSTIMULATION; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; TIME;

ADULT; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHOTIC STIMULATION; PSYCHOMOTOR PERFORMANCE; REACTION TIME; TIME FACTORS; YOUNG ADULT;

EID: 84871875680     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2532-9     Document Type: Article

References (43)

1. Back-Madruga C., Boone KB, Chang L, Grob C.S., Lee A., Nations H, Poland R.E. (2003) Neuropsychological effects of 3,4-methylene-dioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 17:446-459
2. Bosker WM, Kuypers KPC, Conen S, Ramaekers J.G. (2010) Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacology: 1-8
3. Busto U, Bendayan R, Sellers E.M. (1989) Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokin 16:1-26
4. Clemens KJ, McGregor IS, Hunt G.E., Cornish J.L. (2007) MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 26:9-15
5. Cole J, Sumnall H, Grob C. (2002) Sorted: ecstasy facts and fiction. Psychologist 15:464-467
6. Cruickshank CC, Dyer K.R. (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085-1099
7. Degenhardt L, Barker B, Topp L. (2004) Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 99:187-195
8. Degenhardt L, Coffey C, Carlin J.B., Moran P., Patton G.C. (2007) Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction 102:1269-1279
9. Dumont GJH, Schoemaker RC, Touw D.J., Sweep FCGJ, Buitelaar JK, Van Gerven JMA, Verkes RJ (2010) Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol 24:155-164
10. Fernández-Serrano M.J., Pérez-García M, Verdejo-García A (2011) What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav R 35:377-406
11. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M., Laiacona M, Capitani E (1996) Trail making test: normative values from287 normal adult controls. Ital J Neurol Sci 17:305-309
12. Green AR, Mechan AO, Elliott J.M., O'Shea E, Colado M.I. (2003) The pharmacology and clinical pharmacology of 3,4-methylenediox-ymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508
13. Hart CL, Gunderson EW, Perez A, Kirkpatrick M.G., Thurmond A., Comer SD, Foltin R.W. (2008) Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsycho-pharmacol 33:1847-1855
14. Johnson BA, Ait-Daoud N, Wells L.T. (2000) Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-metham-phetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacol 22:504-512
15. Kalechstein AD, Newton TF, Green M. (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychi Clin N 15:215-220
16. Kalechstein AD, De La Garza II R, Mahoney III JJ, Fantegrossi WE, Newton TF (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 189:531-537
17. Kuypers KPC, Ramaekers J.G. (2005) Transient memory impairment after acute dose of 75 mg 3.4-methylenedioxymethamphetamine. J Psychopharmacol 19:633-639
18. Kuypers KPC, Ramaekers J.G. (2007) Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacol 189:557-563
19. Lamers CTJ, Ramaekers JG, Muntjewerff N.D., Sikkema KL, Samyn N, Read NL, Brookhuis K.A., Riedel W.J. (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17:379-387
20. Lamers CTJ, Rizzo M, Bechara A., Ramaekers J. (2006) Simulated driving and attention of repeat users of MDMA and THC compared with THC users and non-drug-using controls. Transportation Research Record, (1969), pp. 50-57. ISBN: 0309099781; 978-030909978-3
21. Liechti ME, Vollenweider F.X. (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274
22. McCann UD, Mertl M, Eligulashvili V., Ricaurte G.A. (1999) Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: a controlled study. Psychopharmacol 143:417-425
23. McCann UD, Peterson SC, Ricaurte G.A. (2007) The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users. Neuropsychopharmacol 32:1695-1706
24. Moon M, Do KS, Park J, Kim D. (2007) Memory impairment in methamphetamine dependent patients. Int J Neurosci 117:1-9
25. Parrott AC (1999) Does cigarette smoking cause stress? Am Psychol 54:817-820
26. Parrott AC (2000) Human research on MDMA (3,4-methylenediox- ymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42:17-24
27. Parrott AC, Gibbs A, Scholey A.B., King R., Owens K, Swann P, Ogden E., Stough C. (2011) MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology: 1-10
28. Pirona A, Morgan M.J. (2010) An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J Psychopharmacol 24:175-185
29. Ramaekers JG, Kuypers KPC (2006) Acute effects of 3,4-methyl- enedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuro-psychopharmacol 31:1048-1055
30. Ryan J, Croft K, Mori T., Wesnes K, Spong J, Downey L., Kure C, Lloyd J, Stough C (2008) An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol 22:553-562
31. Salo R, Nordahl TE, Galloway G.P., Moore CD, Waters C, Leamon M.H. (2009) Drug abstinence and cognitive control in methamphetamine-dependent individuals. J Subst Abuse Treat 37:292-297
32. Scott JC, Woods SP, Matt G.E., Meyer RA, Heaton RK, Atkinson JH, Grant I. (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297
33. Shappell SA, Kearns GL, Valentine J.L., Neri DF, DeJohn C.A. (1996) Chronopharmacokinetics and chronopharmacodynamics of dex-tromethamphetamine in man. J Clin Pharmacol 36:1051-1063
34. Silber BY, Papafotiou K, Croft R.J., Ogden E., Swann P, Stough C. (2005) The effects of dexamphetamine on simulated driving performance. Psychopharmacol 179:536-543
35. Silber BY, Croft RJ, Papafotiou K, Stough C. (2006) The acute effects of D-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacol 187:154-169
36. Stough C, Downey LA, Lloyd J, Silber B., Redman S, Hutchison C, Wesnes K., Nathan P.J. (2008) Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res 22:1629-1634
37. Stough C, Downey LA, King R, Papafotiou K., Swann P, Ogden E. (2011) The acute effects of 3,4-methylenedioxymethamphet-amine and methamphetamine on driving: a simulator study. Accid Anal Prev. doi:10.1016/j.aap.2011.08.017
38. Thomasius R, Zapletalova P, Petersen K., Buchert R, Andresen B, Wartberg L., Nebeling B, Schmoldt A (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psycho-pharmacol (Oxford, England) 20:211-225
39. Wesnes K, Pincock C. (2002) Practice effects on cognitive tasks: a major problem? Lancet Neurol 1:473
40. Wesnes KA, Ward T, McGinty A., Petrini O. (2000) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacol 152:353-361
41. White SR (2002) Amphetamine toxicity. Sem Resp Crit Care M 23:27-36
42. Winstock AR, Griffiths P, Stewart D. (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depen 64:9-17
43. Zakzanis KK, Campbell Z, Jovanovski D. (2007) The neuropsychology of ecstasy (MDMA) use: a quantitative review. Human Psychopharm Clin 22:427-435